Dr. William A. Ross, MD

Dr. Ross practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Ross' NPI, 1477635787, was assigned on October 19, 2006. Dr. Ross graduated from UC Irvine School of Medicine in 1982. Dr. Ross holds Texas license G9523.

Dr. Ross' primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Ross' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ross practices. Vendor and product names are available with a free account.

Gastroenterology is Dr. Ross' primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Ross is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Ross' licenses on file in 11 states: Texas, California, Florida, Arizona, Mississippi, Washington, Alabama, Georgia, Louisiana, Oklahoma and Tennessee.

Dmand AI lists colonoscopy, esophagus, stomach, or upper small intestine surgery, gastrointestinal bleeding, pancreas or bile duct endoscopy (ERCP) and upper GI endoscopy among the conditions Dr. Ross treats.

CMS data shows 635 Medicare services from Dr. Ross across 15 procedure codes in 2024, for 343 Medicare patients. Medicare paid $73,167 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 343 Medicare patients who saw Dr. Ross in 2024. The largest group is 65 to 74, with 178 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ross' median patient age at 73, with 42% women.

In 2024, Dr. Ross wrote 36 Medicare Part D claims for 21 patients. 97% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $181 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Ross for performance year 2024, reported as part of a group. Dr. Ross accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ross as offering telehealth. CMS counts 380 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Ross, more than 97% of the clinicians it reports for that procedure.

Dmand AI links 53 papers to Dr. Ross, published from 2007 to 2023. 2011 was the busiest year, with 5. The most frequent topics are Pancreatic Neoplasms, Stents and Adenocarcinoma. Dr. Ross has published most often in Gastrointest Endosc. Dr. Ross' most frequent co-authors are Manoop S. Bhutani, MD, Jeffrey H. Lee, MD and Patrick M. Lynch, JD, MD.

CMS Open Payments shows 17 general payments to Dr. Ross from 9 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 89% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $4,133.

Dr. Ross graduated from UC Irvine School of Medicine in 1982.

Dr. Ross is in network with 8 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.